Correspondence 0001193125-23-132460 from ACELYRIN, Inc. (SLRN) (CIK 0001962918)
ACELYRIN, Inc. (SLRN) (CIK 0001962918)
Date: May 2, 2023 · CIK: 0001962918 · Accession: 0001193125-23-132460
AI Filing Summary & Sentiment
File numbers found in text: 333-271244
Letter
Morgan Stanley & Co. LLC
1585 Broadway
New York, New York 10036
Jefferies LLC
520 Madison Avenue
New York, New York 10022
Cowen and Company, LLC
599 Lexington Avenue
New York, New York 10022
Piper Sandler & Co.
800 Nicollet Mall, Suite 800
Minneapolis, Minnesota 55402
May 2, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attn: Cindy Polynice, Suzanne Hayes, Ibolya Ignat, Vanessa Robertson
Re: ACELYRIN, INC.
Registration Statement on Form S-1, as amended (File No. 333-271244)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of ACELYRIN, INC. (the “Company”) for acceleration of the effective date of the above-referenced Registration Statement on Form S-1 so that it becomes effective as of 4:00 p.m. Eastern time on May 4, 2023, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Cooley LLP, request by telephone that such Registration Statement be declared effective.
Pursuant to Rule 460 under the Act, we, as representatives of the several underwriters, wish to advise you that there will be distributed to each underwriter or dealer, who is reasonably anticipated to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
Morgan Stanley & Co. LLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Jefferies LLC 520 Madison Avenue New York, New York 10022 Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Piper Sandler & Co. 800 Nicollet Mall, Suite 800 Minneapolis, Minnesota 55402 May 2, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Cindy Polynice, Suzanne Hayes, Ibolya Ignat, Vanessa Robertson Re: ACELYRIN, INC. Registration Statement on Form S-1, as amended (File No. 333-271244) Request for Acceleration of Effective Date Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of ACELYRIN, INC. (the “Company”) for acceleration of the effective date of the above-referenced Registration Statement on Form S-1 so that it becomes effective as of 4:00 p.m. Eastern time on May 4, 2023, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Cooley LLP, request by telephone that such Registration Statement be declared effective. Pursuant to Rule 460 under the Act, we, as representatives of the several underwriters, wish to advise you that there will be distributed to each underwriter or dealer, who is reasonably anticipated to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus. We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. Very truly yours, Morgan Stanley & Co. LLC Jefferies LLC Cowen and Company, LLC Piper Sandler & Co. Acting severally on behalf of themselves and the several Underwriters named in Schedule I hereto By: Morgan Stanley & Co. LLC By: /s/ Frank Tang Name: Frank Tang Title: Executive Director By: Jefferies LLC By: /s/ Michael Brinkman Name: Michael Brinkman Title: Managing Director, Joint US Head of Biopharmaceuticals By: Cowen and Company, LLC By: /s/ Bill Follis Name: Bill Follis Title: Managing Director By: Piper Sandler & Co. By: /s/ Chad Huber Name: Chad Huber Title: Co-Head of ECM [Signature Page to the Underwriters’ Acceleration Request] 2